Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 27Mesothelioma, Malignant 14Solid Tumors 11Mesothelioma 10Advanced Solid Tumor 8Solid Tumor 5Advanced Solid Tumors 4Carcinoma, Non-Small-Cell Lung 3Solitary Fibrous Tumor, Pleural 2Uterine Cervical Neoplasms 1Unspecified Childhood Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Penile Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Metastatic Solid Tumors 1Malignant Neoplasmas 1Lung Neoplasms 1Locally Advanced or Metastatic Solid Tumours 1Cholangiocarcinoma of the Gallbladder 1Advanced Solid Tumours 1Advanced Solid Tumour 1Advanced Cancer 1Advance Solid Tumors 1Adult Solid Tumor 1

Interventions

Gemcitabine 1Everolimus 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma of the Gallbladder × Gemcitabine × Other solid neoplasm × Clear all
NCT00949949 2017-01-12

Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy

Mayo Clinic

Phase 1 Completed
38 enrolled
GastrointestinalGenitourinaryOther solid neoplasm

Cholangiocarcinoma of the Gallbladder

Data powered by HemOnc (CC BY 4.0) Colophon âš¡